Title:
METHOD FOR PRODUCING ARYLAMIDE DERIVATIVE
Document Type and Number:
WIPO Patent Application WO/2023/003014
Kind Code:
A1
Abstract:
The present disclosure provides, for example, a method for producing 2-(4-cyclopropyl-2-fluoroanilino)-3,4-difluoro-5-[[3-fluoro-2-(methylsulfamoylamino)pyridin-4-yl]methyl]benzamide or a pharmacologically acceptable salt thereof, or a pharmacologically acceptable solvate of the compound or a salt, the method comprising a step for reacting (2-amino-3-fluoropyridin-4-yl)methanol with methyl chloroformate and N,N-dimethylaminopyridine in acetonitrile to obtain (2-amino-3-fluoropyridin-4-yl)methylmethyl carbonate. According to the present disclosure, provided is a method which is for producing a specific arylamide derivative that has RAF/MEK complex stabilizing activity and/or MEK inhibitory activity and is useful for treating or preventing cell proliferative diseases, in particular, cancer, and by which an arylamide derivative can be obtained with a small number of steps.
More Like This:
Inventors:
KUWATA KAZUAKI (JP)
SOMEYA HIDEHISA (JP)
SOMEYA HIDEHISA (JP)
Application Number:
PCT/JP2022/028187
Publication Date:
January 26, 2023
Filing Date:
July 20, 2022
Export Citation:
Assignee:
CHUGAI PHARMACEUTICAL CO LTD (JP)
International Classes:
C07D213/76; A61K31/44; A61K31/4436; A61P35/00; B01J31/22; B01J31/24; C07B61/00; C07D213/73; C07D333/66; C07D409/12
Domestic Patent References:
| WO2006011466A1 | 2006-02-02 | |||
| WO2005028426A1 | 2005-03-31 | |||
| WO2021149776A1 | 2021-07-29 | |||
| WO2006011466A1 | 2006-02-02 | |||
| WO2007091736A1 | 2007-08-16 |
Foreign References:
| JP2016034900A | 2016-03-17 | |||
| CH5126766A4 |
Other References:
NAT. REV. CLIN. ONCOL, vol. 15, 2018, pages 709 - 720
MOLECULES, vol. 22, 2017, pages e1551
N. ENGL. J. MED., vol. 367, 2012, pages 1694 - 1703
JAMA, vol. 317, no. 18, 2017, pages 1844 - 1853
ANN. ONCOL., vol. 26, no. 5, 2015, pages 894 - 901
CANCER RES., vol. 73, no. 13, 2013, pages 4050 - 4060
CANCER CELL, vol. 25, no. 5, 2014, pages 697 - 710
J. CLIN. ONCOL., vol. 35, no. 15, 2017
NAT. REV. CLIN. ONCOL., vol. 11, 2014, pages 385 - 400
BIOORG. MED. CHEM. LETT., vol. 18, no. 24, 2008, pages 6501 - 6504
BIOORG. MED. CHEM. LETT., vol. 23, no. 8, 2013, pages 2384 - 2390
CHEM. MED. CHEM., vol. 10, no. 12, 2015, pages 2004 - 2013
ACS MEDCHEM. LETT., vol. 5, no. 4, 2014, pages 309 - 314
MOLECULES, vol. 22, 2017, pages e1551
N. ENGL. J. MED., vol. 367, 2012, pages 1694 - 1703
JAMA, vol. 317, no. 18, 2017, pages 1844 - 1853
ANN. ONCOL., vol. 26, no. 5, 2015, pages 894 - 901
CANCER RES., vol. 73, no. 13, 2013, pages 4050 - 4060
CANCER CELL, vol. 25, no. 5, 2014, pages 697 - 710
J. CLIN. ONCOL., vol. 35, no. 15, 2017
NAT. REV. CLIN. ONCOL., vol. 11, 2014, pages 385 - 400
BIOORG. MED. CHEM. LETT., vol. 18, no. 24, 2008, pages 6501 - 6504
BIOORG. MED. CHEM. LETT., vol. 23, no. 8, 2013, pages 2384 - 2390
CHEM. MED. CHEM., vol. 10, no. 12, 2015, pages 2004 - 2013
ACS MEDCHEM. LETT., vol. 5, no. 4, 2014, pages 309 - 314
Attorney, Agent or Firm:
HASEGAWA Yoshiki et al. (JP)
Download PDF: